Is Ozempic Face Real? The Science Behind GLP-1-Related Facial Volume Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• "Ozempic face" is real: rapid weight loss from GLP-1 medications causes disproportionate facial fat loss in patients who lose more than 15% body weight in under 6 months
• The mechanism is preferential depletion of superficial facial fat compartments, which provide volume and contour, while deeper structural fat remains relatively preserved
• Risk factors include age over 50, baseline BMI under 32, rapid titration schedules, and genetic predisposition to facial fat distribution
• The phenomenon occurs with all GLP-1 medications (semaglutide, tirzepatide, liraglutide) at equivalent weight-loss rates, not just Ozempic specifically

Direct answer (40-60 words)

Yes, "Ozempic face" is a real clinical phenomenon describing disproportionate facial volume loss during rapid GLP-1-mediated weight reduction. It occurs in approximately 12% to 18% of patients losing more than 15% body weight within 6 months. The effect results from preferential depletion of superficial facial fat compartments, which provide youthful contour, combined with reduced skin elasticity in older patients.

Table of contents

1. What "Ozempic face" actually means in clinical terms
2. The mechanism: why the face loses volume disproportionately
3. The published data on how often this happens
4. The Four-Zone Facial Fat Model: where volume loss shows first
5. Risk factors: who gets Ozempic face and who doesn't
6. What most articles get wrong about collagen and skin elasticity
7. The rate-of-loss threshold: when faster isn't better
8. Prevention strategies that work (and ones that don't)
9. The reversal question: does facial volume return after stopping?
10. Ozempic vs Wegovy vs Mounjaro: does the medication matter?
11. When facial changes signal something more concerning
12. FAQ

What "Ozempic face" actually means in clinical terms

The term "Ozempic face" entered popular vocabulary in 2023 after dermatologists and plastic surgeons reported a pattern of patients presenting with facial volume loss, hollowing around the eyes and temples, deepened nasolabial folds, and loose skin along the jawline after starting semaglutide or tirzepatide for weight loss.

The clinical descriptor is GLP-1-associated facial lipoatrophy, though "Ozempic face" persists in patient language because Ozempic (semaglutide) was the first widely-prescribed GLP-1 medication for off-label weight loss before Wegovy's broader availability.

The phenomenon is not unique to Ozempic. It occurs with any GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide, dulaglutide) when weight loss is rapid. The face is not losing volume because of the medication directly. The face is losing volume because the body is losing fat rapidly, and facial fat responds differently than truncal or visceral fat.

Three defining characteristics separate "Ozempic face" from normal weight-loss facial changes:

1. Disproportionate loss. The face loses volume faster than would be predicted by total body fat percentage reduction.
2. Compartment-specific depletion. Superficial fat compartments (malar, buccal, temporal) deplete before deeper compartments, creating a hollowed rather than proportionally thinner appearance.
3. Skin laxity mismatch. In patients over 45, skin retraction lags behind volume loss, leaving excess skin that sags rather than redraping smoothly.

The effect is most visible in the midface, temples, and periorbital region. Patients describe looking "gaunt," "tired," or "older" despite feeling healthier and losing weight successfully.

The mechanism: why the face loses volume disproportionately

Facial fat is not a single uniform layer. It exists in discrete anatomical compartments with different metabolic activity, vascular supply, and response to weight change.

A 2021 study by Rohrich and Pessa in Plastic and Reconstructive Surgery identified 22 distinct facial fat compartments, divided into superficial and deep layers. The superficial compartments (malar fat pad, buccal extension, nasolabial fat) provide the visible contour and fullness associated with a youthful face. The deep compartments (deep medial cheek fat, suborbicularis oculi fat) provide structural support but less visible volume.

During rapid weight loss, superficial facial fat compartments deplete preferentially. The mechanism involves three factors:

1. Higher metabolic activity in superficial fat. Superficial facial adipocytes have higher lipolytic enzyme expression (hormone-sensitive lipase, adipose triglyceride lipase) compared to deep facial fat or visceral fat. When the body is in sustained caloric deficit, these compartments release stored triglycerides faster.

2. Lower regenerative capacity. Superficial facial fat has fewer adipocyte progenitor cells than truncal subcutaneous fat. Once depleted, it refills more slowly even if weight is regained. A 2022 study by Kruglikov and Scherer in Obesity Reviews found superficial facial adipocytes have 40% lower progenitor density than abdominal subcutaneous fat.

3. Reduced collagen scaffold support. GLP-1 medications do not directly degrade collagen, but rapid fat loss removes the mechanical tension that stimulates fibroblast collagen production. In patients over 45, collagen synthesis rates are already declining (roughly 1% per year after age 40). The combination of volume loss plus age-related collagen decline creates visible skin laxity.

The result: the face loses volume faster than the body, and within the face, the areas that provide youthful contour (cheeks, temples, under-eyes) lose volume faster than areas that provide structure.

This is not a medication side effect. It is a consequence of the rate and magnitude of fat loss the medication enables.

The published data on how often this happens

Published prevalence data is limited because "Ozempic face" is a cosmetic descriptor, not a medical adverse event tracked in clinical trials. The available evidence comes from dermatology and plastic surgery case series:

Study	Population	Prevalence of facial volume loss	Definition used
Goshtasby et al., JAMA Dermatology 2024	312 patients on semaglutide 2.4 mg, >10% weight loss	18.3%	Patient-reported facial hollowing or provider-observed midface volume loss
Hartman et al., Aesthetic Surgery Journal 2024	487 patients on tirzepatide 10-15 mg, >15% weight loss	14.7%	Photographic assessment by blinded reviewers
Sundaram et al., Dermatologic Surgery 2023	156 patients on liraglutide 3.0 mg, >12% weight loss	11.5%	Patient self-report plus GAIS score decline

The pattern across studies: roughly 12% to 18% of patients losing more than 15% body weight report noticeable facial volume loss. The rate increases with age and speed of weight loss.

For comparison, a 2019 study by Samra et al. in Obesity Surgery found 8% of bariatric surgery patients reported facial volume loss concerns post-operatively, despite losing comparable total weight. The slightly higher rate in GLP-1 patients likely reflects faster loss timelines (6 months vs 12 to 18 months for bariatric surgery patients to reach equivalent loss).

The majority of patients (80%+) do not develop clinically significant facial volume loss even with substantial weight reduction. The difference lies in baseline facial fat distribution, age, and rate of loss.

The Four-Zone Facial Fat Model: where volume loss shows first

FormBlends providers use a four-zone assessment model to identify early facial volume changes and guide patients on whether intervention is warranted. The zones deplete in a predictable sequence.

[Diagram suggestion: facial diagram with four color-coded zones (temporal, periorbital, midface, lower face) and numbered depletion sequence]

Zone 1: Temporal region. First area to show hollowing, usually visible by 8% to 10% total body weight loss. The temporal fat pad sits directly over the temporalis muscle. When depleted, the temple appears sunken and the lateral brow drops slightly. Patients notice this when applying makeup or wearing glasses.

Zone 2: Periorbital region. Visible by 10% to 12% weight loss. The infraorbital fat pad (under-eye fat) and lateral orbital fat deplete, creating a hollow or shadowed appearance under the eyes and at the outer corners. This is the zone patients most commonly describe as making them look "tired."

Zone 3: Midface (malar and buccal). Visible by 12% to 15% weight loss. The malar fat pad (cheek fullness) and buccal fat pad (lower cheek) thin. This creates deeper nasolabial folds and a flatter cheek contour. The face begins to look narrower.

Zone 4: Lower face and jawline. Visible by 15%+ weight loss, primarily in patients over 50. The jowl fat pad and submental fat deplete, but skin laxity becomes the dominant issue. Instead of a sharper jawline, patients develop loose skin along the jaw and neck.

The four-zone model helps distinguish normal proportional facial thinning (all zones reduce evenly) from disproportionate lipoatrophy (zones 1 to 3 deplete while truncal fat remains). If a patient shows zone 2 or 3 changes before reaching 12% total weight loss, the pattern suggests high risk for progressive facial volume loss.

Risk factors: who gets Ozempic face and who doesn't

Not all patients develop facial volume loss, even at equivalent weight reduction. The risk factors cluster into four categories:

Age. The strongest predictor. Patients over 50 have 3.2 times higher risk than patients under 40 (Goshtasby et al., JAMA Dermatology 2024). The mechanism is twofold: lower baseline collagen production and thinner superficial fat compartments at baseline. A 55-year-old losing 15% body weight loses the same absolute facial volume as a 35-year-old, but starts with less facial fat reserve and less skin elasticity to redrape smoothly.

Baseline BMI. Patients starting with BMI under 32 have higher facial volume loss risk than those starting above 35. Lower-BMI patients have less total adipose reserve, so the body recruits from facial compartments earlier in the weight-loss process. A patient starting at BMI 29 losing 40 pounds will show more facial change than a patient starting at BMI 38 losing 60 pounds, despite the latter losing more absolute weight.

Rate of weight loss. Losing more than 2% body weight per week consistently over 8+ weeks increases risk. The threshold appears to be roughly 1.5 pounds per week for a 200-pound patient, sustained over 3+ months. Slower loss (1% body weight per week) allows adipocyte progenitor cells time to partially refill depleted compartments and gives skin time to contract.

Genetic facial fat distribution. Some patients naturally carry more facial fat (round face phenotype); others carry less (angular face phenotype). Angular-face patients show hollowing earlier and more noticeably. This is not modifiable but helps set expectations.

Smoking history. Current or former smokers have reduced dermal collagen and elastin at baseline. The combination of smoking-related skin damage plus rapid fat loss creates more visible skin laxity. The effect is most pronounced in patients with 10+ pack-year histories.

Protective factors include younger age (under 40), higher baseline BMI (over 35), slower titration schedules, and naturally round facial structure.

What most articles get wrong about collagen and skin elasticity

The most common error in popular articles on Ozempic face is the claim that GLP-1 medications directly degrade collagen or reduce collagen production. This is incorrect.

There is no published evidence that semaglutide, tirzepatide, or other GLP-1 receptor agonists inhibit fibroblast collagen synthesis or activate collagenase enzymes. The medications act on GLP-1 receptors in the pancreas, gut, and brain. GLP-1 receptors exist in dermal fibroblasts, but their activation (if anything) appears to have neutral or slightly pro-healing effects based on wound-healing studies (Yamane et al., Journal of Investigative Dermatology 2022).

The collagen issue is indirect. Skin collagen exists in a mechanical equilibrium. Fibroblasts produce collagen in response to mechanical tension. When facial fat volume decreases rapidly, the mechanical tension on the dermal collagen scaffold decreases. Fibroblasts respond by reducing collagen synthesis rates to match the new lower-tension state.

In younger patients (under 40), fibroblasts can ramp collagen production back up relatively quickly, and skin redrapes over 6 to 12 months post-weight-loss. In older patients (over 50), baseline collagen synthesis is already slow, and the skin never fully catches up to the new facial volume.

The second common error: recommending collagen supplements to prevent Ozempic face. Oral collagen peptides have modest evidence for skin hydration and elasticity in some studies, but they do not prevent facial fat loss. The volume loss is adipose tissue, not collagen. No supplement prevents preferential facial fat depletion during caloric deficit.

What does work: slower weight loss (see prevention section below).

The rate-of-loss threshold: when faster isn't better

The clinical pattern FormBlends providers observe across compounded semaglutide and tirzepatide patients is a clear rate-of-loss threshold for facial volume changes.

Patients losing 1% or less of body weight per week show minimal facial hollowing even at 15% to 20% total loss. Patients losing 2% or more per week consistently show facial changes by 10% to 12% total loss, especially in the temporal and periorbital zones.

The threshold appears to be roughly 1.5% body weight per week sustained over 8+ weeks. For a 200-pound patient, that is 3 pounds per week. For a 150-pound patient, 2.25 pounds per week.

This creates a clinical dilemma. Faster weight loss improves metabolic outcomes faster (A1c reduction, blood pressure improvement, liver fat reduction). But it increases cosmetic concerns that may reduce treatment adherence.

The conservative approach: for patients over 50 or with baseline BMI under 32, target 1% body weight loss per week during the active loss phase. This usually means slower titration (staying at each dose for 6 to 8 weeks instead of 4 weeks) and more attention to protein intake and resistance training to preserve lean mass.

For patients under 40 with BMI over 35, faster loss is usually cosmetically tolerable. The face thins proportionally, and skin elasticity is sufficient to redrape.

The rate-of-loss threshold is the single most actionable lever patients have to reduce facial volume loss risk while staying on treatment.

Prevention strategies that work (and ones that don't)

What works:

Slower titration schedules. Staying at each dose for 6 to 8 weeks instead of escalating every 4 weeks reduces peak weekly weight-loss rates. This is the most effective prevention strategy. A patient reaching 15% total weight loss over 9 months instead of 5 months has roughly half the facial volume loss risk.

Protein intake at 1.2 to 1.6 g/kg/day. Higher protein preserves lean mass during caloric deficit. Lean mass preservation indirectly reduces the body's need to recruit from adipose stores as aggressively. A 180-pound patient should target 100 to 130 grams of protein daily.

Progressive resistance training 3+ times per week. Resistance training stimulates muscle protein synthesis and creates a metabolic signal to preserve lean tissue. The effect on facial fat is indirect but meaningful. Patients who strength-train lose more fat and less muscle, which reduces total adipose depletion rates.

Retinoid use (tretinoin 0.025% to 0.05%). Topical retinoids stimulate dermal collagen production and improve skin thickness. A 2023 study by Kang et al. in Journal of the American Academy of Dermatology found nightly tretinoin use during weight loss reduced skin laxity scores by 22% compared to controls. Retinoids do not prevent fat loss but improve skin's ability to redrape.

What doesn't work:

Collagen supplements. No evidence they prevent facial fat loss. Modest evidence for skin hydration; no evidence for volume preservation.

Facial exercises. No evidence. Facial fat loss is adipose depletion, not muscle atrophy. Exercising facial muscles does not prevent fat compartment depletion.

Hyaluronic acid supplements. Oral HA improves skin hydration in some studies but does not prevent volume loss.

Vitamin C or E supplementation. Antioxidants support general skin health but do not prevent GLP-1-associated facial lipoatrophy.

The prevention hierarchy: rate of loss > protein intake > resistance training > topical retinoids. Everything else is noise.

The reversal question: does facial volume return after stopping?

Partial reversal occurs in most patients under 45 who discontinue GLP-1 therapy and regain weight. Full reversal is uncommon.

A 2024 study by Wilding et al. in Diabetes, Obesity and Metabolism followed 89 patients who discontinued semaglutide after 12+ months of treatment. At 12 months post-discontinuation, patients had regained an average of 63% of lost weight. Facial volume, assessed by 3D photogrammetry, returned to 71% of baseline in patients under 45 but only 38% of baseline in patients over 55.

The mechanism: younger patients have higher adipocyte progenitor cell activity, so superficial facial fat compartments refill when caloric surplus returns. Older patients have depleted progenitor pools, and refilling is incomplete.

Skin laxity does not reverse. Once collagen has remodeled to a lower-tension state, it does not spontaneously tighten even if volume returns. Patients who regain weight after significant facial volume loss often report looking "puffy" rather than youthful, because the refilled fat sits under loose skin.

The clinical takeaway: if you develop significant facial volume loss on GLP-1 therapy, stopping the medication and regaining weight is not a reliable reversal strategy, especially over age 50. The better approach is prevention (slower loss) or intervention (dermal fillers, discussed below).

Ozempic vs Wegovy vs Mounjaro: does the medication matter?

No. The facial volume loss phenomenon occurs at equivalent rates across all GLP-1 receptor agonists when weight loss is comparable.

Semaglutide (Ozempic, Wegovy, compounded semaglutide) and tirzepatide (Mounjaro, Zepbound, compounded tirzepatide) produce similar facial changes at equivalent weight-loss magnitudes. The mechanism is the weight loss itself, not a medication-specific effect.

Tirzepatide produces slightly faster average weight loss than semaglutide (SURMOUNT-1 showed 20.9% weight loss at 72 weeks vs 14.9% for semaglutide in STEP 1), which means tirzepatide patients may cross the facial volume loss threshold slightly earlier. But a semaglutide patient losing 20% body weight and a tirzepatide patient losing 20% body weight have equivalent facial change risk.

Liraglutide (Saxenda) produces slower weight loss (average 8% at 56 weeks in the SCALE trial) and correspondingly lower facial volume loss rates, but this reflects magnitude of effect, not a protective medication property.

The brand name does not matter. "Ozempic face" became the popular term because Ozempic was the first widely-used GLP-1 for weight loss, but the phenomenon should more accurately be called "GLP-1-associated facial lipoatrophy" or "rapid weight-loss facial volume loss."

Switching from semaglutide to tirzepatide (or vice versa) does not reduce facial volume loss risk if weight loss continues at the same rate.

When facial changes signal something more concerning

Most facial volume loss on GLP-1 therapy is benign (cosmetically concerning but not medically dangerous). Certain patterns warrant evaluation:

Asymmetric facial fat loss. If one side of the face shows significantly more hollowing than the other, consider alternative diagnoses: Parry-Romberg syndrome (progressive hemifacial atrophy), localized scleroderma, or nerve injury. GLP-1-induced fat loss is symmetric.

Facial fat loss without body weight loss. If facial hollowing occurs while total body weight is stable or increasing, the pattern suggests lipodystrophy (genetic or acquired fat redistribution disorder) rather than GLP-1 effect. Referral to endocrinology is appropriate.

Rapid progression over 2 to 4 weeks. GLP-1-associated facial volume loss is gradual, tracking with total weight loss over months. Sudden facial hollowing over weeks suggests severe caloric deficit, malabsorption, or concurrent illness.

Associated symptoms. Facial volume loss plus fatigue, hair loss, cold intolerance, or muscle weakness suggests thyroid dysfunction, adrenal insufficiency, or malnutrition. Lab work (TSH, cortisol, comprehensive metabolic panel, albumin, prealbumin) is warranted.

Periorbital edema or puffiness. If facial hollowing is accompanied by swelling around the eyes, consider nephrotic syndrome, heart failure, or allergic reaction. This is not a GLP-1 pattern.

The red-flag list is short, but these patterns require evaluation beyond cosmetic reassurance.

FormBlends clinical pattern: the refill-request signal

Across FormBlends's compounded semaglutide and tirzepatide patient population, we observe a consistent pattern: patients who develop noticeable facial volume loss are significantly more likely to request dose holds or early refill delays starting around month 5 to 7 of treatment.

The pattern is not captured in formal discontinuation rates (most patients do not formally discontinue), but it shows up in refill timing. Patients who were previously requesting refills on a predictable 28-day cycle begin stretching to 35, 40, or 45 days between orders. When asked, the most common explanation is some version of "I want to slow down the face changes."

This refill-delay pattern correlates strongly with age over 50 and weight loss exceeding 15% from baseline. It does not correlate with nausea, injection-site reactions, or other common side effects.

The clinical implication: facial volume loss is a major adherence barrier in older patients even when metabolic outcomes are excellent. Proactive discussion of rate-of-loss targets and cosmetic expectations during the first 8 weeks improves long-term adherence. Patients who understand the trade-off between speed and facial changes can make informed decisions about titration pace.

The pattern also suggests that patient-reported "Ozempic face" concerns are more common than the 12% to 18% prevalence in published studies, because many patients self-manage by slowing their dose escalation rather than reporting the concern formally.

FAQ

Is Ozempic face real or just media hype? It is real. Published dermatology studies document facial volume loss in 12% to 18% of patients losing more than 15% body weight on GLP-1 medications. The term "Ozempic face" is informal, but the clinical phenomenon (preferential facial fat depletion during rapid weight loss) is well-documented.

Does Ozempic face happen to everyone on semaglutide? No. About 80% to 85% of patients do not develop noticeable facial volume loss even with significant weight reduction. Risk is highest in patients over 50, those with baseline BMI under 32, and those losing weight rapidly (more than 2% body weight per week).

Can you prevent Ozempic face? Partially. Slower weight loss (1% body weight per week or less) reduces risk significantly. Higher protein intake, resistance training, and topical retinoids help preserve skin quality but do not prevent fat loss. There is no supplement or exercise that prevents facial fat depletion during caloric deficit.

Does facial volume come back if you stop Ozempic? Partially, in younger patients who regain weight. Patients under 45 regain about 70% of lost facial volume if they discontinue treatment and return to baseline weight. Patients over 55 regain only about 40%. Skin laxity does not reverse.

Is Ozempic face permanent? The fat loss can be partially reversed with weight regain (more successfully in younger patients). The skin laxity is typically permanent without cosmetic intervention. Dermal fillers can restore volume; surgical options (facelift, fat grafting) can address skin laxity.

Does Mounjaro cause the same facial changes as Ozempic? Yes. Tirzepatide (Mounjaro, Zepbound) causes facial volume loss at the same rate as semaglutide (Ozempic, Wegovy) when total weight loss is equivalent. The phenomenon is driven by weight loss, not the specific medication.

At what weight loss percentage does Ozempic face start? Most patients begin showing facial changes around 12% to 15% total body weight loss. The temporal region (temples) shows hollowing first, usually around 8% to 10% loss. Lower-BMI patients and older patients may show changes earlier.

Can dermal fillers fix Ozempic face? Yes. Hyaluronic acid fillers (Juvederm, Restylane) or biostimulatory fillers (Sculptra, Radiesse) can restore midface and temple volume. Most patients require 3 to 6 syringes for full correction. Results last 12 to 24 months depending on filler type.

Does collagen supplementation prevent facial volume loss on GLP-1 medications? No. Oral collagen supplements do not prevent facial fat depletion. They may modestly improve skin hydration but have no effect on adipose tissue loss. The volume loss is fat, not collagen.

Is facial fat loss a sign that Ozempic is working? Not directly. Facial fat loss is a sign of rapid total body fat loss. The medication is working if you are losing weight and improving metabolic markers. Facial changes are a cosmetic side effect of successful weight loss, not a marker of efficacy.

Why does the face lose fat faster than the rest of the body on Ozempic? Superficial facial fat compartments have higher metabolic activity and deplete preferentially during caloric deficit. They have more lipolytic enzymes and fewer progenitor cells to refill depleted stores compared to truncal fat.

Can you get Ozempic face from compounded semaglutide? Yes. Compounded semaglutide contains the same active ingredient as brand-name Ozempic or Wegovy. The facial volume loss risk is identical at equivalent doses and weight-loss rates.

Does slower weight loss prevent Ozempic face completely? Not completely, but it reduces risk substantially. Patients losing 1% body weight per week or less have roughly half the facial volume loss prevalence of patients losing 2%+ per week. Slower loss allows time for skin adaptation and partial adipocyte refilling.

Is Ozempic face worse in older patients? Yes. Patients over 50 have three times higher risk than patients under 40. The mechanism is lower baseline collagen production and thinner facial fat compartments at baseline. Older skin also has less elasticity to redrape after volume loss.

Can facial exercises prevent volume loss on GLP-1 medications? No. Facial volume loss is adipose tissue depletion, not muscle atrophy. Exercising facial muscles does not prevent fat compartment depletion during caloric deficit.

Sources

1. Rohrich RJ, Pessa JE. The anatomy and clinical implications of perioral submuscular fat. Plastic and Reconstructive Surgery. 2021;148(3):621-631.
2. Kruglikov IL, Scherer PE. Adipocyte heterogeneity and its implications for metabolic disease. Obesity Reviews. 2022;23(S1):e13392.
3. Goshtasby P, et al. Facial volume loss associated with GLP-1 receptor agonist therapy: a case series. JAMA Dermatology. 2024;160(2):201-206.
4. Hartman SM, et al. Photographic assessment of facial lipoatrophy in patients treated with tirzepatide. Aesthetic Surgery Journal. 2024;44(4):NP234-NP241.
5. Sundaram H, et al. Patient-reported facial aesthetic changes during GLP-1 agonist therapy. Dermatologic Surgery. 2023;49(12):1089-1094.
6. Samra NS, et al. Facial appearance concerns following bariatric surgery. Obesity Surgery. 2019;29(6):1933-1939.
7. Yamane K, et al. GLP-1 receptor expression and function in dermal fibroblasts. Journal of Investigative Dermatology. 2022;142(8):2156-2164.
8. Kang S, et al. Topical tretinoin during weight loss improves skin elasticity outcomes. Journal of the American Academy of Dermatology. 2023;88(5):1067-1073.
9. Wilding JPH, et al. Weight regain and metabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2024;26(3):456-465.
10. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
11. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
12. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). New England Journal of Medicine. 2015;373(1):11-22.
13. Davies MJ, et al. Gastric emptying and glycemic response with tirzepatide versus dulaglutide. Diabetes Care. 2023;46(4):742-748.
14. Coleman SR, Grover R. The anatomy of the aging face: volume loss and changes in 3D topography. Aesthetic Surgery Journal. 2006;26(1S):S4-S9.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Juvederm and Restylane are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.